Bamlanivimab Use in a Military Treatment Facility
Article
[키워드] acute respiratory syndrome
Administered
administration
Admission
analyzed
approval
approved
Arm
bamlanivimab
Care
caused
cohort study
coronavirus
coronavirus disease
COVID-19
COVID-19 patient
death
declined
diagnosed
Disease progression
facility
FDA
Follow-up
Guidance
help
hospital
Hospital admission
Hospitalization
information
initial
inpatient admission
institutional review board
intravenous
IRB
lack
Mild-to-moderate
monoclonal antibody
Patient
patients
patients with SARS-CoV-2
placebo group
Prevent
Primary outcome
progression
provided
receiving
replicated
reported
required
retrospective
risk
risk factor
SARS-CoV-2
secondary outcome
self-reported symptom
severe COVID-19
small sample size
Spread
statistical significance
statistically significant
Study design
Symptom
treated
Treatment
treatment group
virus-neutralizing
was obtained
were given
Wuhan, China
[DOI] 10.1093/milmed/usab188 PMC 바로가기
[DOI] 10.1093/milmed/usab188 PMC 바로가기